Endothelial Leukocyte Cell–Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulin‐Like and Epidermal Growth Factor–Like Domains 1 Signaling in Liver Fibrosis
Tingting Su, Yasuko Iwakiri – 15 February 2020
Fecal Microbiome Distinguishes Alcohol Consumption From Alcoholic Hepatitis But Does Not Discriminate Disease Severity
Ekaterina Smirnova, Puneet Puri, Mark D. Muthiah, Kalyani Daitya, Robert Brown, Naga Chalasani, Suthat Liangpunsakul, Vijay H. Shah, Kayla Gelow, Mohammed S. Siddiqui, Sherry Boyett, Faridoddin Mirshahi, Masoumeh Sikaroodi, Patrick Gillevet, Arun J. Sanyal – 14 February 2020
Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma
Johann Felden, Augusto Villanueva – 14 February 2020 – Patient selection and organ allocation for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) relies predominantly on clinical parameters, such as tumor burden (ie, radiological imaging). Patients transplanted within Milan criteria have outstanding outcomes with a 5‐ and 10‐year survival of 70% and 55%, respectively. Tumor recurrence after transplantion is rare in these patients (10%); however, treatment options upon recurrence are generally limited, and outcomes are poor.
Lifestyle Modification Leads to Spatially Variable Reduction in Hepatic Steatosis in Potential Living Liver Donors
Hyo Jung Park, Kyoung Won Kim, Jae Hyun Kwon, Jeongjin Lee, Taeyong Park, Heon‐Ju Kwon, Gi‐Won Song, Sung‐Gyu Lee – 14 February 2020 – The spatial variability of hepatic fat reduction in potential living liver donors with hepatic steatosis (HS) who undergo lifestyle modification has not been investigated. Here, we aimed to examine the intrasegmental and intersegmental variability of changes in liver attenuation on computed tomography (CT) in potential living liver donors with HS after diet modification and exercise.
Susceptibility of Rat Steatotic Liver to Ischemia–Reperfusion Is Treatable With Liver‐Selective Matrix Metalloproteinase Inhibition
Xiangdong Wang, Christopher J. Walkey, Ana C. Maretti‐Mira, Lei Wang, Deborah L. Johnson, Laurie D. DeLeve – 14 February 2020
Hepatitis E Virus Infection in the United States: Current Understanding of the Prevalence and Significance in the Liver Transplant Patient Population and Proposed Diagnostic and Treatment Strategies
Maureen Whitsett, David M. Feldman, Ira Jacobson – 14 February 2020 – Hepatitis E virus (HEV), of the family Herpesviridae, is a virus that infects nearly 20 million people per year throughout the world. HEV is most commonly transmitted via the fecal‐oral route and has long been described as a virus that afflicts only those in resource‐poor countries. However, HEV has been detected in numerous animal carriers, various food sources, and even in human blood products in resource‐rich regions of the world.
Estrogen Acts Through Estrogen Receptor 2b to Regulate Hepatobiliary Fate During Vertebrate Development
Saireudee Chaturantabut, Arkadi Shwartz, Maija K. Garnaas, Kyle LaBella, Chia‐Cheng Li, Kelli J. Carroll, Claire C. Cutting, Nadine Budrow, Amrita Palaria, Daniel A. Gorelick, Kimberly D. Tremblay, Trista E. North, Wolfram Goessling – 14 February 2020
Letter to the Editor: Safety First: Favoring Prophylactic/Preemptive Over Delayed Treatment in D+/R− Transplants
Norah A. Terrault, Jordan J. Feld – 14 February 2020
Fecal Microbiome Distinguishes Alcohol Consumption From Alcoholic Hepatitis But Does Not Discriminate Disease Severity
Ekaterina Smirnova, Puneet Puri, Mark D. Muthiah, Kalyani Daitya, Robert Brown, Naga Chalasani, Suthat Liangpunsakul, Vijay H. Shah, Kayla Gelow, Mohammed S. Siddiqui, Sherry Boyett, Faridoddin Mirshahi, Masoumeh Sikaroodi, Patrick Gillevet, Arun J. Sanyal – 14 February 2020
New Drugs for NASH and HIV Infection: Great Expectations for a Great Need
Giovanni Guaraldi, James B. Maurice, Catia Marzolini, Kenneth Monteith, Jovana Milic, Emmanuel Tsochatzis, Sanjay Bhagani, Caryn G. Morse, Jennifer C. Price, Patrick Ingiliz, Maud Lemoine, Giada Sebastiani, the SHIVER Network – 13 February 2020 – In recent years, there has been an increasing number of clinical trials for the treatment of nonalcoholic steatohepatitis (NASH). People living with human immunodeficiency virus (PLWH) are commonly excluded from these studies, usually due to concerns over drug–drug interactions associated with antiretroviral therapy.